NextBioMedical Sets All-Time High Quarterly Sales for Third Consecutive Quarter... Accelerates Pipeline Enhancement

by Jang Hyowon

Published 04 Dec.2025 07:40(KST)

NextBioMedical Sets All-Time High Quarterly Sales for Third Consecutive Quarter... Accelerates Pipeline Enhancement

Mirae Asset Securities evaluated NextBioMedical in its corporate analysis report, stating that the company has demonstrated solid growth by breaking its all-time highest quarterly sales record for three consecutive quarters.

According to Mirae Asset Securities, NextBioMedical's sales in the third quarter of this year reached 4.9 billion KRW, a 125% increase compared to the same period last year, once again setting a new record for the highest quarterly sales. By product, sales were as follows: NexPowder 4.3 billion KRW (up 144% year-on-year), Nexsphere 300 million KRW (up 25% year-on-year), and NexsphereF 300 million KRW (up 57% year-on-year), with all product lines showing balanced growth.

Operating profit also turned positive, reaching 370 million KRW (operating margin of 7.5%), thanks to the leverage effect from top-line growth.

Kim Chunghyun, a researcher at Mirae Asset Securities, stated, "The company is penetrating the global market by developing pipelines with clinical superiority over existing therapies and forming partnerships with global companies. Furthermore, it is expected to actively pursue a platform strategy encompassing both the enhancement of pipeline performance and the expansion of indications."

In particular, Kim highlighted, "The company is developing a next-generation NexPowder with added pharmaceutical ingredients and aims to further strengthen hemostatic performance to increase the likelihood of being listed in clinical guidelines. For NexsphereF, clinical trials are underway to expand its indications, and promising data has been observed in proof-of-concept studies."

Meanwhile, in November, NextBioMedical completed the Pre-Submission (Pre-sub) process with the U.S. Food and Drug Administration (FDA) for its gelatin-based vascular embolization medical device, Nexsphere™ (Nexsphere), which the company developed.